This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.
This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.
Adverse events reporting information can be found in the footer of this page.
Prescribing information (external link)
Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adults (alone or in combination with methotrexate [MTX]) who have responded inadequately to disease-modifying anti-rheumatic drug therapy.3
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.
‘I am a Consultant Rheumatologist and Physician at Portsmouth Hospitals University NHS Trust, here to discuss the impact of comorbidities in psoriatic arthritis, how they shape disease burden and quality of life, and why careful screening is essential. Drawing on my own clinical experience, I explore the challenges my patients face and highlight real‑world and clinical evidence showing how Cosentyx may support the management of eligible patients...'
Dr Nicola Gullick
Consultant Rheumatologist and Honorary lecturer at the University of Warwick
Watch our latest recording featuring Dr Nicola Gullick, as she discusses the impact of comorbidities in PsA, drawing on her own clinical experience to highlight how they influence disease burden, quality of life and treatment considerations.
'I am a Consultant Rheumatologist and Physician at Portsmouth Hospitals University NHS Trust, here to discuss aiming for remission in patients with psoriatic disease who have responded inadequately to previous treatments. Let’s meet Jerry, a 52-year-old male working as a carer with a history of depression, and who was diagnosed with psoriasis (PsO) in 1990 and psoriatic arthritis (PsA) in 2000. He presented with dactylitis and enthesitis manifestations…’
Dr Gurdeep Dulay
Consultant Rheumatologist and Physician at Portsmouth Hospitals University NHS Trust
Watch our latest recording featuring Dr Gurdeep Dulay , as he discusses one of his long-term patients with PsA, exploring treatment failure with a TNFi and how treatment decision can support eligible PsA patients to achieve remission.
‘I am an academic rheumatologist for Leeds in the UK, here to discuss long-term use of Cosentyx in people with PsA. Let’s start with Lisa, a 45-year-old female who was diagnosed with PsA in 2006. She presented with joint symptoms affecting multiple joints, inflammation at entheseal sites and moderate skin disease…’
Prof. Philip Conaghan
Consultant Rheumatologist and Director of the NIHR Leeds Biomedical Research Centre
Watch our latest recording featuring Professor Philip Conaghan as he takes us through one of his long-term patients with PsA, exploring key data and treatment decisions over the years.
The most frequently reported adverse reactions are upper respiratory tract infections (17.1%) (most frequently nasopharyngitis, rhinitis). Caution should be exercised when considering the use of Cosentyx in patients with a chronic infection or a history of recurrent infection. If a patient develops a serious infection, the patient should be closely monitored and Cosentyx should not be administered until the infection resolves. Patients should be evaluated for tuberculosis infection prior to initiating treatment with Cosentyx. Cosentyx should not be given to patients with active tuberculosis. In patients with latent tuberculosis, anti‑tuberculosis therapy should be considered prior to initiation of Cosentyx. Cosentyx is not recommended in patients with IBD. If a patient develops signs and symptoms of IBD or experiences an exacerbation of pre-existing inflammatory bowel disease, Cosentyx should be discontinued and appropriate medical management should be initiated.3
Please refer to the SmPC for full safety information before prescribing.
*Since first indication in 2015 for eligible adults with moderate to severe PsO.1,2
This promotional event has been organised and funded by Novartis Pharmaceuticals UK Ltd.
UK | January 2026 | FA-11538677-1
Therapeutic Indications3
Cosentyx is indicated for the treatment of moderate to severe PsO in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active PsA in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe HS (acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.3
AS, ankylosing spondylitis; ERA, enthesitis-related arthritis; HS, hidradenitis suppurativa; IL-17, interleukin 17A; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, psoriasis; SmPC, summary of product characteristics; TNFi, tumor necrosis factor inhibitor.
References
European Medicines Agency. Cosentyx : EPAR - Medicine overview. EMA/250862/2023. Available at: https://www.ema.europa.eu/en/documents/overview/cosentyx-epar-medicine-overview_en.pdf [Accessed March 2026].
European Medicines Agency. Assessment report: Cosentyx. EMA/CHMP/389874/2014. Available at: https://www.ema.europa.eu/en/documents/assessment-report/cosentyx-epar-public-assessment-report_en.pdf [Accessed March 2026].
Cosentyx® (secukinumab) Summary of Product Characteristics.
ClinicalTrials.gov. Secukinumab search results. Available at: https://www.clinicaltrials.gov/search?term=Secukinumab&aggFilters=status:com%20rec%20act [Accessed March 2026].
Novartis Data on File. Secukinumab (SEC024). February 2026.
UK | March 2026 | FA-11463462-3
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
